Rxrx stock forecast.
Price/Earnings Ratio is a widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Actual EPS (Earnings Per Share). data ...
Nov 30, 2023 · Stock analysis for Recursion Pharmaceuticals Inc (RXRX:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Recursion Pharmaceuticals (NASDAQ: RXRX) stock popped in July, fueled by a game-changing development—a direct investment of $50 million from Nvidia. But, since that month’s peak, RXRX’s ...Wall Street is abuzz with the news of Nvidia’s $50 million investment in Recursion Pharmaceuticals (NASDAQ:RXRX). The biotech company’s stock surged over 120% following the announcement ...5 equities research analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they expect the company's share price to reach $4.80 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 RXRX Stock Rips on Nvidia Investment. Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day.
The Recursion Pharmaceuticals, Inc. stock price gained 7.88% on the last trading day (Friday, 1st Dec 2023), rising from $6.85 to $7.39. During the last trading day …Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share.2013. 550. Chris Gibson. https://www.recursion.com. Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which ...All of that said, let's take a look at the consensus forecast for Wood's newest addition to her flagship fund - an unprofitable biotech stock under $10. About Recursion Pharmaceuticals Headquartered in Salt Lake City, Recursion Pharmaceuticals RXRX is a clinical-stage biotechnology company that is pioneering the use of machine learning and …See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. RXRX's current price target is …NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...
What is Recursion Pharmaceuticals, Inc. (RXRX) stock EPS forecast? Recursion Pharmaceuticals, Inc. missed analysts’ expectations during the last earnings period by 13.16% . Recursion Pharmaceuticals, Inc. reported earnings of -$ 0.43 per share on Nov 9, 2023, while the forecasted EPS was -$ 0.38.
A $50 million private investment from the AI-linked chipmaker sparked a surge in Recursion, which uses machine learning to discover new medicines. The stock more than doubled at the market open ...
Analysts have provided the following ratings for Recursion Pharmaceuticals (NASDAQ:RXRX) within the last quarter: These 7 analysts have an average price target of $18.14 versus the current price ...3 авг. 2023 г. ... RXRX Stock Recursion Pharmaceuticals top stocks to buy in August ... TWLO: Twilio Stock Analysis and Prediction. Financial Depth•800 views.Jul 13, 2023 · The US$14.13 analyst price target for RXRX is 3.5% ... we will estimate the stock's intrinsic value by taking the forecast future cash flows of the company and discounting them back to today's ... Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and …beststocks.comStock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an …RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.
Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.Jul 12, 2023 · For RXRX stock, which has suffered sharp losses against a long-term framework, AI may put the underlying company on the right track again. Still, investors need to be aware of separating the ... Investors looking for stocks that can put up dramatic gains ... (RXRX 7. 88%) have fallen by ... Zynteglo's U.S. launch will be extra difficult to forecast because its strategy involves returning ...Three Fool.com healthcare contributors like Vertex Pharmaceuticals ( VRTX 0.22%), Repligen ( RGEN -2.06%), and Recursion Pharmaceuticals ( RXRX -0.69%). Here's why they believe these three stocks ...Find the latest Recursion Pharmaceuticals, Inc. RXRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range.JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September …Dec 1, 2023 · Based on short-term price targets offered by seven analysts, the average price target for Recursion Pharmaceuticals comes to $15.29. The forecasts range from a low of $9.00 to a high of $33.00 ...
RXRX Quantitative Stock Analysis - Benjamin Graham. November 18, 2023 — 01:00 pm EST. Written by John Reese for Validea ->. Below is Validea's guru fundamental report for RECURSION ...Analysts on Wall Street sometimes assign one-year price targets to stocks that imply massive upside potential. That's what's happening with Recursion …
Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago. These figures are ...RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -435.99% from its current level, while the stock would need to crash -37.83% from its current level to reach the projected low.Complete Recursion Pharmaceuticals Inc. stock information by Barron's. View real-time RXRX stock price and news, along with industry-best analysis.Andrew Hopkins. https://www.exscientia.ai. Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient ...Zolak. Clinical-stage biotech Recursion Pharmaceuticals ( NASDAQ: RXRX) added ~7% in the pre-market Monday after announcing agreements to acquire Cyclica and Valence, two Canadian companies ...According to the current price, Recursion Pharmaceuticals, is 42.39% away from the 52-week high. What are analysts forecasts for Recursion Pharmaceuticals, stock? The 21 analysts offering price ...Explore RXRX - Recursion Pharmaceuticals Inc Stock Price Forecast: Accurate short-term and long-term price predictions up to 2050. ... Stock Calculator; Dow: 35,088. ...
Next reporting date: February 14, 2024: EPS forecast (this quarter) $0.95: Annual revenue (last year) $2.2B: Annual profit (last year) $42.8M: Net profit margin
Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the …
Find the latest Recursion Pharmaceuticals, Inc. (RXRX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and …Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.33 per share a year ago.Dec 1, 2023 · Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.Nov 30, 2023 · Analyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price. 5 equities research analysts have issued 12 month price objectives for Amneal Pharmaceuticals' stock. Their AMRX share price targets range from $3.00 to $7.00. On average, they expect the company's share price to reach $4.80 in the next twelve months. This suggests a possible upside of 9.8% from the stock's current price.30 сент. 2023 г. ... NASDAQ: RXRX. Recursion Pharmaceuticals. Recursion Pharmaceuticals Stock Quote. Market Cap. $2B. Today's Change. (0.43%) $0.03. Current Price.Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 Jul 1 2021 Recursion Pharmaceuticals (RXRX) said Thursday it has signed a lease agreement with Vestar for an additional 100,000 square feet of space to double the size of its Salt Lake City headquarters. In 2018, the biotech firm signed a lease for 100,000 square feet of space at The Gateway complex in downtown Salt Lake City.
In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.Explore RXRX - Recursion Pharmaceuticals Inc Stock Price Forecast: Accurate short-term and long-term price predictions up to 2050. ... Stock Calculator; Dow: 35,088. ... Gil Blum, an analyst from Needham, reiterated the Buy rating on Recursion Pharmaceuticals (RXRX – Research Report). The associated price target is $15.00. Gil Blum’s Buy rating for Recursion ...Instagram:https://instagram. best ppo dental insurance californiatransunion shareablesnyse ldostop stocks for day trading Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...Recursion lost $65.3 million compared to a loss of $56 million in the same period a year ago, and said it had $473.1 million in cash. Jim Halley has no position in any of the stocks mentioned. The ... marc chaikin number one stockbiotechnology etf Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for RXRX stock stock is $15.33, which predicts an … gaming etf Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...Recursion lost $65.3 million compared to a loss of $56 million in the same period a year ago, and said it had $473.1 million in cash. Jim Halley has no position in any of the stocks mentioned. The ...